Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions
Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary
Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country. The establishment of this subsidiary marks an important milestone for Curative Biotech as it expands its reach and presence in the Japanese market. The new entity has been named Curative Biotech Japan K.K. (“Curative Japan”) and will be located at 2-23-12 Shimomeguro Meguro ku, Tokyo 153-0064 Japan.
Related news for (CUBT)
- Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor
- Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
- キュレイティブ・バイオテクノロジー (Curative Biotechnology, Inc.)、テレサ・ヒー博士 (Dr. Theresa Heah) を取締役会に指名することを発表
- Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
- Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors